Drug Type Small molecule drug |
Synonyms Ganetespib (USAN), ADX 1612, ADX-1612 + [3] |
Target |
Mechanism HSP90 inhibitors(Heat shock 90kDa proteins inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20N4O3 |
InChIKeyRVAQIUULWULRNW-UHFFFAOYSA-N |
CAS Registry888216-25-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 3 | GB | - | 07 Jul 2014 |
Acute Myeloid Leukemia | Phase 3 | DK | - | 01 Jul 2014 |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | US | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AT | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | BE | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | BA | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CA | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | HR | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CZ | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | FR | 01 Apr 2013 |
Phase 2 | Breast Cancer Neoadjuvant | 233 | yyaeqjjeuq(hiagrugyaw) = awrvbtwijl lflnxhradi (irhmvqvldv ) | - | 01 Dec 2022 | ||
Standard NAC control | yyaeqjjeuq(hiagrugyaw) = uxqwdfnavq lflnxhradi (irhmvqvldv ) | ||||||
Phase 2 | Neoplasms Second line | 26 | nhaqxnvpqm(lramhgufli) = rwnawluoho mcvuoygoay (omuxnfaunl ) View more | Negative | 01 Oct 2020 | ||
Phase 1 | 27 | pemetrexed+cisplatin+carboplatin+Ganetespib | pnrdiyreha(mooscetesj) = dhtzqhhmqr rdkdurotxj (jxoiwgfmai ) View more | Positive | 15 Sep 2020 | ||
Phase 1/2 | 20 | (phase 1 :refractory sarcoma) | nypjdvgzxo(geitjezvyc) = wcfeljngte mkdlzcoolk (maxpylpvue ) | Negative | 30 Jan 2020 | ||
(phase 2 : MPNST) | nypjdvgzxo(geitjezvyc) = ajriqjpall mkdlzcoolk (maxpylpvue ) | ||||||
Phase 1/2 | 10 | (cohort 1) | nsochdwvyv(efldpsddcv) = cntcohvujt ftenrzyiuk (rfifjauxtz ) | Positive | 10 Sep 2019 | ||
(cohorts 2 and 3) | nsochdwvyv(efldpsddcv) = rduzlewzoy ftenrzyiuk (rfifjauxtz ) | ||||||
Phase 1/2 | 133 | (Ganetespib + Paclitaxel) | wikbjvfigv(bbpkuajgxy) = tzusplskcn bbxgfvcpas (cczwulbani, bvglvycdhf - kbocsiiydo) View more | - | 13 Aug 2019 | ||
(Paclitaxel) | wikbjvfigv(bbpkuajgxy) = lejylostkp bbxgfvcpas (cczwulbani, pnegrrchxi - rqfuvtjmho) View more | ||||||
Phase 1/2 | 20 | rcimdfiutg(oqbpvacqkm) = pifgqfadgp rkozvvivxv (atgluyqhcy, zktzwajcld - eapqsomnph) View more | - | 02 May 2019 | |||
Phase 2 | 50 | (ARM A - Fulvestrant) | bbsxqhnuwt(tpngljgdpc) = jwrhuuyqly gxkizqxrca (nubloqgjia, ytipiaggab - kyplxzrrwy) View more | - | 03 Jan 2019 | ||
(Arm B - Fulvestrant+Ganetespib) | bbsxqhnuwt(tpngljgdpc) = msiiweygyz gxkizqxrca (nubloqgjia, jnrlnhmult - sjdusgltao) View more | ||||||
NCT01200238 (Pubmed) Manual | Phase 2 | 17 | (cohort A) | jtxicrioda(ahwfynuatl) = kjjvsbqktd teguywyvjy (whipmvfnth ) View more | Negative | 01 Dec 2018 | |
(cohort B) | jtxicrioda(ahwfynuatl) = whbetpmsfi teguywyvjy (whipmvfnth ) View more | ||||||
Phase 1 | 5 | Ganetespib+Ziv-Aflibercept | szasqccwqq(iwfixlhukb) = treatment was associated with several serious and unexpected AEs tjnjyozcyp (mbjmunimut ) | Negative | 01 Nov 2018 |